Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

9 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > »    
 
  
Reply to this topic

RMD, RESMED INC
Capercat
post Posted: Feb 5 2009, 08:14 AM
  Quote Post


Posts: 23


I'm in two minds whether to short this or not. Chart is on the slide, but a good result could boost the stock...

 
dan.heath
post Posted: Jan 31 2009, 07:10 PM
  Quote Post


Posts: 685
Thanks: 5


Hmm... Interest rates likely to go lower, could be big drop, Aussie $ likely to fall , their not reporting early so earnings should be on track, which was up. Cautious US investors maybe be seeking out quality health stocks. I maybe right, make a change, this sp might very well keep going up after earnings announcement. I'll hold a little longer I think. Anyone care to guess what this sp might end up at, for mine I'd reckon $7.50 to $8.00 might see it out.

 
dan.heath
post Posted: Jan 28 2009, 12:46 PM
  Quote Post


Posts: 685
Thanks: 5


This one's sp been heading north for a while now , US investors, are they investing in quality health stocks? How far for how long is the question.Will they continue to invest after upcoming earnings announcement? In my opinion, in this financial climate, they might.
RESMED TO WEBCAST SECOND QUARTER 2009

EARNINGS CONFERENCE CALL

Sydney, Australia, January 27, 2009 -- RESMED INC. (ASX: RMD), announced today that on Friday, February 6, 2009, it will release its earnings for the second quarter of fiscal year 2009, ended December 31, 2008. ResMed will issue an earnings press release after 8.00 a.m. Australian Eastern Daylight Time (AEDT) and will host a conference call to review its quarterly results, market trends, and future outlook.

The conference call is scheduled to begin at 8.30 a.m. Australian Eastern Daylight Time (AEDT) and will be webcast on ResMed's website at www.resmed.com. The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:

9:30 p.m. London (February 5, 2009)

1.30 p.m. San Diego (February 5, 2009)

TO PARTICIPATE in the conference call, please call one of the below numbers at least 10 minutes before the call begins and identify yourself to the operator:

International: +1 617-847-8712

Conference Name: ResMed Inc. 2Q 2009 Earnings Call

Participant Passcode: 28551812

The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:

International: +1 617-801-6888

Passcode: 50840361

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. Further information can be obtained by contacting Connie Bienfait at ResMed Inc. at +1 (858) 746-2736, or by visiting the Company's Web site at www.resmed.com.



 
dan.heath
post Posted: Nov 12 2008, 09:26 AM
  Quote Post


Posts: 685
Thanks: 5


A little late this post , release a few days old.
QUOTE
RESMED INC ANNOUNCES RECORD FINANCIAL RESULTS FOR THE
QUARTER ENDED SEPTEMBER 30, 2008
SYDNEY, Australia, November 7, 2008 - ResMed Inc. (ASX: RMD) today announced record revenue and
income results for the quarter ended September 30, 2008. Revenue for the quarter was US$217.9 million, a
17% increase over the quarter ended September 30, 2007. For the current quarter, income from operations was
US$36.6 million and net income was US$28.0 million, an increase of 15% and 16%, respectively, compared to
the quarter ended September 30, 2007. Diluted earnings per share for the quarter ended September 30, 2008
was US$0.36, an increase of 16% compared to the quarter ended September 30, 2007.
SG&A costs were US$71.3 million for the quarter, an increase of US$8.5 million or 13% over the same period in
fiscal 2007. The increase in SG&A was primarily due to expenses necessary to support sales growth and the
net appreciation of international currencies against the US dollar. SG&A costs were 33% of revenue in the
September 2008 quarter, compared to 34% in the same period in fiscal 2007.
R&D expenses during the quarter were US$17.3 million, or approximately 8% of revenue. R&D expenses
increased 33% year over year. The increase in research and development outlays reflects ResMed’s continuing
commitment to innovation within its product portfolio, as well as an ongoing commitment to clinical research and
product development. The increase in R&D was also due to the net appreciation of international currencies
against the US dollar.
Amortization of acquired intangibles of US$1.9 million (US$1.3 million net of tax) incurred during the quarter
ended September 30, 2008, consisted of amortization of assets associated with our acquisitions of Resprecare,
Hoefner, Saime and PolarMed. Stock-based compensation costs incurred during the quarter ended September
30, 2008 of US$5.6 million (US$3.9 million net of tax) consisted of expenses associated with stock options
granted to employees and with our employee stock purchase plan.
Inventory, at US$145.6 million, decreased by US$12.7 million compared to June 30, 2008. Accounts receivable
days sales outstanding, at 75 days, increased by 3 days compared to June 30, 2008.
Kieran T. Gallahue, President and Chief Executive Officer, commented, "In the first quarter of fiscal 2009, we
continued to show strong and balanced growth across the globe. Sales outside of the Americas totaled
US$104.3 million, an 18% increase over the prior year quarter, while sales in the Americas were US$113.6
million, an increase of 16% over the prior year quarter. Cash flow from operations for the September quarter was
a record US$67.9 million. Our robust operating cash flows, in addition to our strong and conservative balance
sheet, position us well in the current economic environment.”
Mr. Gallahue continued, “As we move into the second quarter of fiscal 2009, we are well-positioned to grow
revenues. We are encouraged by the sales growth of our S8II flow generator platform and Swift LT nasal pillows
mask. Our new product release schedule remains active, particularly in both the mask and bilevel categories.
We are introducing new masks in both Europe and the US during the second quarter, including the Americas
release of Swift LT for Her. This is the first and only nasal pillows product designed and marketed specifically for
female patients. Additionally, we released a series of new bilevels in Europe and the VPAP S in the Americas.
All of these bilevels utilize our patented Easy-Breathe motor technology, providing unparalleled performance at
up to 90% less noise than other leading competitors. We continue to invest aggressively in developing new
technologies and products to serve the growing sleep-disordered breathing marketplace, while maintaining
prudent fiscal management.”
“Global progress in our efforts to educate and validate the role of sleep-disordered breathing in comorbid patient
populations took a major step forward in the last three months. In September, the European Society of
Cardiologists published guidelines for the diagnosis and treatment of acute and chronic heart failure. For the first
time, the guidelines noted that patients with symptomatic heart failure frequently have sleep-related disorders
(central or obstructive sleep apnea) and recommended treatment with CPAP for patients diagnosed with
obstructive sleep apnea. This follows just three months after the International Diabetes Federation issued a
consensus statement on sleep-disordered breathing and type II diabetes, where the substantial value of
identifying and treating diabetic patients suffering from sleep-disordered breathing was also recognized and
recommended. The increasing awareness among comorbidity specialists augurs well for the efforts and
investment we are making in new markets including diabetes, occupational health and cardiology.”


 
dan.heath
post Posted: Oct 28 2008, 11:55 AM
  Quote Post


Posts: 685
Thanks: 5


RESMED TO WEBCAST FIRST QUARTER 2009
EARNINGS CONFERENCE CALL
Sydney, Australia, October 24, 2008 -- RESMED INC. (ASX: RMD), announced today that on Friday, November 7, 2008, it will release its earnings for the first quarter of fiscal year 2009, ended September 30, 2008. ResMed will issue an earnings press release after 8:00 a.m. Australian Eastern Daylight Time (AEDT) and will host a conference call to review its quarterly results, market trends, and future outlook.
The conference call is scheduled to begin at 8:30 a.m. Australian Eastern Daylight Time (AEDT) and will be webcast on ResMed's website at www.resmed.com. The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.
International conference call times will be:
9:30 p.m. London (November 6, 2008)
1:30 p.m. San Diego, CA (November 6, 2008)
TO PARTICIPATE in the conference call, please call the below number at least 10 minutes before the call begins and identify yourself to the operator:
International: +1 (617) 614-3673
Conference Name: ResMed Inc. 1Q 2009 Earnings Call
Participant Passcode: 49480223
The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:
International: +1 (617) 801-6888
Passcode: 99471059
ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. Further information can be obtained by contacting Matthew Borer at ResMed Inc. at +1 (858) 746-2280; Brett Sandercock at ResMed Limited at (02) 8884-2090, or by visiting the Company’s Web site at www.resmed.com.
- End -

 
dan.heath
post Posted: Aug 6 2008, 11:30 AM
  Quote Post


Posts: 685
Thanks: 5


Good pick up this morning 50 cents up. Might be in for a sustained run with aussie $ likely to head down against the US $ , as interest rates fall. Management is predicting solid growth in 09.
QUOTE
RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE
QUARTER AND YEAR ENDED JUNE 30, 2008
SYDNEY, Australia, August 6, 2008 - ResMed Inc. (ASX: RMD) today announced revenue and income results for the quarter ended June 30, 2008. Revenue for the quarter was a record US$235.2 million, a 23% increase over the quarter ended June 30, 2007. For the current quarter, income from operations and net income were US$37.0 million and US$29.6 million, respectively. Diluted earnings per share for the quarter ended June 30, 2008 was US$0.38. For the quarter ended June 30, 2008, an additional expense of US$3.1 million has been recognized as a charge to cost of sales in relation to the voluntary recall we announced in April 2007 related to our previous series of S8 flow generators. We do not expect any further significant costs in relation to this recall. Excluding product recall expenses, diluted earnings per share was US$0.40, an increase of 14% compared to the quarter ended June 30, 2007. Excluding product recall expenses, gross margin was 58.3%, mainly as the result of encouraging growth in the U.S. market.
SG&A costs were US$77.4 million for the quarter, an increase of US$12.2 million, or 19%, over the same period in fiscal 2007. SG&A costs were 33% of revenue in the June quarter, compared to 34% in the same period in fiscal 2007. The increase in SG&A was primarily due to the addition of selling and administration personnel and related expenses to support sales growth. The increase in SG&A was also due to the net appreciation of international currencies against the U.S. dollar.
R&D expenses during the quarter were US$17.6 million or approximately 7% of revenue. R&D expenses increased 24% year over year. The increase in research and development outlays reflects the continuing commitment to innovation within our product portfolio, as well as an ongoing commitment to clinical research and product development. The increase in R&D was also due to the net appreciation of international currencies against the U.S. dollar.
Amortization of acquired intangibles of US$2.1 million, incurred during the quarter ended June 30, 2008, consisted of amortization of acquired intangible assets associated with our acquisitions of Resprecare, Hoefner, Saime, PulmoMed and PolarMed. Stock-based compensation costs incurred during the quarter ended June 30, 2008, of US$5.3 million, consisted of expenses associated with stock options granted to employees and the employee stock purchase plan.
For the year ended June 30, 2008, revenue was a record US$835.4 million, an increase of 17% over the US$716.3 million for the year ended June 30, 2007. For the year ended June 30, 2008, income from operations and net income were US$143.0 million and US$110.3 million, respectively. GAAP diluted earnings per share for the year ended June 30, 2008 was US$1.40 per diluted share.
Inventory was US$158.3 million as of June 30, 2008, a decrease of US$11.2 million compared to the March 31, 2008 level of US$169.5 million. Accounts receivable days sales outstanding, at 72 days, decreased one day when compared to 73 days for the March 31, 2008 quarter.
Kieran T. Gallahue, Chief Executive Officer, commented, "In the fourth quarter of fiscal 2008, overall sales outside of the Americas totaled US$123.0 million, a 32% increase over the prior year quarter. Americas’ sales were US$112.2 million, an increase of 14% over the prior year quarter. Operating cash flow for the June quarter was a record US$56.8 million and we repurchased US$51.7 million in stock which puts our fiscal year total at US$99.5 million representing 2.6 million shares.”
Mr. Gallahue continued, “We were pleased with the strong and balanced growth achieved by our global operations this past quarter, particularly the accelerated growth experienced in the US market. We are encouraged by the traction gained from our recent product releases: the S8 II series of flow generators and the Swift LT nasal pillows mask.
“Our industry received positive signals that it is poised for continued growth. Home sleep testing took another step forward as both national and local Medicare rulings were released and private insurers, such as the country’s largest insurer, Anthem, issued updated coverage policies. Medicare competitive bidding
implementation was delayed 18-24 months, a positive signal for the home medical equipment industry. Lastly, the International Diabetes Federation published an important consensus statement on sleep apnea and diabetes. The diabetes community now has an official recommendation to screen all type 2 diabetes patients suspected of sleep apnea. ResMed is well positioned to deliver strong growth in fiscal year 2009.”
About ResMed
ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals for the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
ResMed will host a conference call at 6:30 a.m. Australian Eastern Standard Time (AEST) today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's web site at www.resmed.com or by dialing +1 (617) 213-8898 and entering conference I.D. No. 31223107. Please allow extra time prior to the call to visit the web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing +1 (617) 801-6888 and entering conference I.D. No. 24669616.
Further information can be obtained by contacting Matthew Borer at ResMed Inc., San Diego, at +1 (858) 746-2280; Brett Sandercock at ResMed Limited, Sydney, on +61 (2) 8884-2090; or by visiting the Company's multilingual web site at www.resmed.com.
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development, new markets for the Company's products and the impact of future developments related to the recently announced product recall, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. The Company cannot be certain that it has accurately predicted the costs of the product recall, which could change in response to additional feedback from ongoing discussions with the FDA and with various foreign regulatory bodies. In addition, the product recall could affect the Company’s reputation. Additional risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's web site.
- More -
Now 62 cents up.

 

Featured Stock Stories





dan.heath
post Posted: Jul 1 2008, 11:48 AM
  Quote Post


Posts: 685
Thanks: 5


In reply to: drrc on Monday 30/06/08 08:23pm

Good pick up there drrc, SP up forty cents this morning, some are taking the article/ rumour seriously.

 
drrc
post Posted: Jun 30 2008, 08:23 PM
  Quote Post


Posts: 2,469
Thanks: 289


Linde eyes ResMed

* Michael West
* June 30, 2008 - 7:34PM


Could it be that another great Australian technology company is about to vanish offshore? Sleep disorder company ResMed is being stalked by German industrial and medical gases giant, the Linde Group.

While Linde, which boasts an enterprise value of 21 billion euro ($34 billion), is close to its trading highs, ResMed is trading not too shy of its lows for the year.

Even at a 50% premium to its prevailing stock price, a takeover bid for ResMed would likely be viewed as opportunistic. Even if it were an agreed cash bid, which is the speculation.

This is a company with minimal debt that dominates a global niche market growing at 20% a year.

Along with Cochlear and CSL, ResMed rounds off the troika of Australian biotechnology stocks that have made it big on the world stage.

However, its shares have been wallowing in the wake of a weak US dollar and discounting by archrival Respironics.

Respironics was recently acquired by Royal Philips.

ResMed and Respironics control roughly 40% of the market for CPAP devices portable machines which combat sleep apnea. Fisher & Paykel is the third player with about 7%.

Sleep apnea is responsible for around half of all sleep disorders. As more causal links emerge between various sleep disorders and the likes of heart failure, stroke and the onset of diabetes, demand for medical devices has increased. They work.

ResMed's growth, however, has been constrained by the predominance of its machines in US hospitals. The US is Resmed's largest market and health-care costs there are prohibitive.

As it ramps up sales of portable devices however, its profit margins are expected to improve.

Strategically, a takeover of ResMed makes perfect sense for Linde, which recently took over industrial gases group BOC and already has distribution channels into health care and hospital markets.

Locally, BOC Australia was sold not to Linde, but to Wesfarmers.

Though Wesfarmers has its enormous acquisition of Coles to digest, ResMed would make an appetising deal indeed as the WA conglomerate already has distribution in medial gases.

http://business.theage.com.au/linde-eyes-r...80630-2zdo.html

 
donnaleighh
post Posted: Feb 21 2008, 04:14 PM
  Quote Post


Posts: 336
Thanks: 12


In reply to: Spicer69 on Friday 02/11/07 04:44pm

Hey Spicer... you getting the sense that the RMD play is near again? Seems the pattern is coming into play again - although I would like to see the DMI close out a bit more - watching closely now - but sensing it may be close to a buy in with tight stops esp. in current times - interested your thoughts as you seem to pick this play very sweetly indeed. Cheers, Donna

 
Spicer69
post Posted: Dec 26 2007, 09:36 AM
  Quote Post


Posts: 324
Thanks: 1


Sill holding.....I love it when a plan comes together......Merry Xmas...... hypocrite.gif

 
 


9 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING